再鼎医药(09688.HK) 首季经营亏损按年收窄20%，经调整经营亏损按年收窄25%。总裁兼首席营运官Josh Smiley表示，公司正稳步迈向于今年第四季实现非公认会计准则下扭亏为盈的目标，又指2025年是公司的蜕变之年，目前正在全力推进年初制定的各项关键目标，展望未来预料贝玛妥珠单抗和KarXT等后期管线产品，将与核心产品卫伟迦一同推动业绩增长。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-09 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.